These findings underscore that tau PET may be a more robust marker for disease severity in clinical AD than CSF p-tau, and that tau PET may serve as an important outcome variable for tracking disease severity, for instance, during treatment with disease-modifying or symptomatic drugs. Here, MAPT is linked to Alzheimer disease.